Country: United States
Language: English
Source: NLM (National Library of Medicine)
METOPROLOL TARTRATE (UNII: W5S57Y3A5L) (METOPROLOL - UNII:GEB06NHM23)
Rubicon Research Private Limited
METOPROLOL TARTRATE
METOPROLOL TARTRATE 100 mg
ORAL
PRESCRIPTION DRUG
Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol. Oral Metoprolol tartrate tablets therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event. (See DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS and WARNINGS). Hypertension and Angina Metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see WARNINGS). Hypersensitivity to metoprolol and related de
Metoprolol tartrate tablets USP are available containing 25 mg, 50 mg or 100 mg of metoprolol tartrate USP. The 25 mg tablets are film-coated, round, biconvex, pink, scored (debossed with R 25 on one side and scored on the other side). Bottles of 100 ……NDC 49930-001-01 Bottles of 1000 …..NDC 49930-001-02 The 50 mg tablets are film-coated, round, biconvex, pink, scored (debossed with R 50 on one side and scored on the other side). Bottles of 100 ……NDC 49930-002-01 Bottles of 1000 …..NDC 49930-002-02 The 100 mg tablets are film-coated, round, biconvex, pink, scored (debossed with R 100 on one side and scored on the other side). Bottles of 100 ……NDC 49930-003-01 Bottles of 1000 …..NDC 49930-003-02 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Manufactured by: Rubicon Research Private Limited Ambernath, Dist: Thane, 421506, INDIA Revised: 11/2014
Abbreviated New Drug Application
METOPROLOL TARTRATE - METOPROLOL TARTRATE TABLET, FILM COATED RUBICON RESEARCH PRIVATE LIMITED ---------- METOPROLOL TARTRATE - METOPROLOL TARTRATE TABLET, FILM COATED RUBICON RESEARCH PRIVATE LIMITED DESCRIPTION Metoprolol tartrate is a selective beta -adrenoreceptor blocking agent, available as 25 mg, 50 mg and 100 mg tablets for oral administration. Metoprolol tartrate is (±)-1-(isopropylamino)-3-[_p_-2- methoxyethyl)phenoxy]-2-propanol (2:1) _dextro_-tartrate salt. Its structural formula is: Metoprolol tartrate, USP is a white, crystalline powder with a molecular weight of 684.82. It is very soluble in water; freely soluble in methylene chloride, in chloroform, and in alcohol; slightly soluble in acetone; and insoluble in ether. Each tablet for oral administration contains 25 mg, 50 mg or 100 mg of Metoprolol Tartrate and the following inactive ingredients: Lactose Monohydrate; Colloidal Silicon Dioxide; Hypromellose; Magnesium Stearate; Microcrystalline Cellulose; Polyethylene glycol; Titanium Dioxide; Sodium Starch Glycolate; Talc and D and C Red #30 Aluminium Lake. CLINICAL PHARMACOLOGY MECHANISM OF ACTION Metoprolol is a beta -selective (cardioselective) adrenergic receptor blocker. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta adrenoreceptors, chiefly located in the bronchial and vascular musculature. Clinical pharmacology studies have demonstrated the beta-blocking activity of metoprolol, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Hypertension The mechanism of the antihypertensive effects of beta-blocking agents has not been fully elucidated. However, several possible mechanisms have been proposed: (1) competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased cardiac Read the complete document